Advertisement

Amino Acids

, Volume 35, Issue 4, pp 739–752 | Cite as

Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations

  • A. Lupi
  • R. Tenni
  • A. Rossi
  • G. Cetta
  • A. ForlinoEmail author
Review Article

Abstract

Here we summarized what is known at the present about function, structure and effect of mutations in the human prolidase. Among the peptidases, prolidase is the only metalloenzyme that cleaves the iminodipeptides containing a proline or hydroxyproline residue at the C-terminal end. It is relevant in the latest stage of protein catabolism, particularly of those molecules rich in imino acids such as collagens, thus being involved in matrix remodelling. Beside its intracellular functions, prolidase has an antitoxic effect against some organophosphorus molecules, can be used in dietary industry as bitterness reducing agent and recently has been used as target enzyme for specific melanoma prodrug activation. Recombinant human prolidase was produced in prokaryotic and eukaryotic hosts with biochemical properties similar to the endogenous enzyme and represents a valid tool both to better understand the structure and biological function of the enzyme and to develop an enzyme replacement therapy for the prolidase deficiency (PD). Prolidase deficiency is a rare recessive disorder caused by mutations in the prolidase gene and characterized by severe skin lesions. Single amino acid substitutions, exon splicing, deletions and a duplication were described as causative for the disease and are mainly located at highly conserved amino acids in the sequence of prolidase from different species. The pathophysiology of PD is still poorly understood; we offer here a review of the molecular mechanisms so far hypothesized.

Keywords

Prolidase Proline Prolidase deficiency Genotype–phenotype correlation 

Notes

Acknowledgments

We gratefully acknowledge Prof. Vittorio Bellotti and Prof. Giampaolo Merlini for providing the mass spectrometry technology at the “Laboratori di biotecnologie”, IRCCS Policlinico S. Matteo, Pavia and P. Arcidiaco, “Centro Grandi Strumenti”, University of Pavia, for Edman’s sequencing. This work was supported by MIUR 2006 (Grant n. 2006050235), Fondazione Cariplo and the European Community (FP6, “EuroGrow” project, LSHM-CT-2007-037471).

References

  1. Abbott C, Yu DM, Woollatt E et al (2000) Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 267:6140–6150PubMedGoogle Scholar
  2. Arata J, Hatakenaka K, Oono T (1986) Effect of topical application of glycine and proline on recalcitrant leg ulcers of prolidase deficiency. Arch Dermatol 122:626–627PubMedGoogle Scholar
  3. Berardesca E, Fideli D, Bellosta M et al (1992) Blood transfusions in the therapy of a case of prolidase deficiency. Br J Dermatol 126:193–195PubMedGoogle Scholar
  4. Bissonnette R, Friedmann D, Giroux JM et al (1993) Prolidase deficiency: a multisystemic hereditary disorder. J Am Acad Dermatol 29:818–821PubMedGoogle Scholar
  5. Blau N, Niederwieser A, Shmerling DH (1988) Peptiduria presumably caused by aminopeptidase-P deficiency. A new inborn error of metabolism. J Inherit Metab Dis 11(Suppl 2):240–242PubMedGoogle Scholar
  6. Bockelmann W (1995) The proteolytic system of sterter and non-starter bacteria: components and their importance for cheese ripening. Int Dairy J 5:977–994Google Scholar
  7. Boright AP, Scriver CR, Lancaster GA et al (1989) Prolidase deficiency: biochemical classification of alleles. Am J Hum Genet 44:731–740PubMedGoogle Scholar
  8. Buckel P (1996) Recombinant proteins for therapy. Trends Pharmacol Sci 17:450–456PubMedGoogle Scholar
  9. Busek P, Malík R, Sedo A (2003) Dipeptidyl peptidase-IV activity and/or structure homologues (DASH) and their substrates in cancer. Intl J Biochem Cell Biol 36:408–421Google Scholar
  10. Butterworth J, Priestman DA (1985) Presence in human cells and tissues of two prolidases and their alteration in prolidase deficiency. J Inherit Metab Dis 8:193–197PubMedGoogle Scholar
  11. Cheng TC, Harvey SP, Chen GL (1996) Cloning and expression of a gene encoding a bacterial enzyme for decontamination of organophosphorus nerve agents and nucleotide sequence of the enzyme. Appl Environ Microbiol 62:1636–1641PubMedGoogle Scholar
  12. Cohen MH, Williams G, Johnson JR et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935–942PubMedGoogle Scholar
  13. Copik AJ, Swierczek SI, Lowther WT et al (2003) Kinetic and spectroscopic characterization of the H178A methionyl aminopeptidase from Escherichia coli. Biochemistry 42:6283–6292PubMedGoogle Scholar
  14. Cottrell GS, Hooper NM, Turner AJ (2000) Cloning, expression, and characterization of human cytosolic aminopeptidase P: a single manganese(II)-dependent enzyme. Biochemistry 39:15121–15128PubMedGoogle Scholar
  15. Desagher S, Martinou JC (2000) Mitochondria as the central control point of apoptosis. Trends Cell Biol 10:369–377PubMedGoogle Scholar
  16. Di Rocco M, Fantasia AR, Taro M et al (2007) Systemic lupus erythematosus-like disease in a 6-year-old boy with prolidase deficiency. J Inherit Metab Dis 30:814PubMedGoogle Scholar
  17. Druker BJ (2002) STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 8(Suppl 4):S14–18PubMedGoogle Scholar
  18. Du X, Tove S, Kast-Hutcheson K et al (2005) Characterization of the dinuclear metal center of Pyrococcus furiosus prolidase by analysis of targeted mutants. FEBS Lett 579:6140–6146PubMedGoogle Scholar
  19. Dyne K, Zanaboni G, Bertazzoni M et al (2001) Mild, late-onset prolidase deficiency: another Italian case. Br J Dermatol 144:635–636PubMedGoogle Scholar
  20. Emmerson KS, Phang JM (1993) Hydrolysis of proline dipeptides completely fulfills the proline requirement in a proline-auxotrophic Chinese hamster ovary cell line. J Nutr 123:909–914PubMedGoogle Scholar
  21. Endo F, Matsuda I, Ogata A et al (1982) Human erythrocyte prolidase and prolidase deficiency. Pediatr Res 16:227–231PubMedGoogle Scholar
  22. Endo F, Motohara K, Indo Y et al (1987) Immunochemical studies of human prolidase with monoclonal and polyclonal antibodies: absence of the subunit of prolidase in erythrocytes from a patient with prolidase deficiency. Pediatr Res 22:627–633PubMedGoogle Scholar
  23. Endo F, Tanoue A, Nakai H et al (1989) Primary structure and gene localization of human prolidase. J Biol Chem 264:4476–4481PubMedGoogle Scholar
  24. Endo F, Tanoue A, Ogata T et al (1988) Immunoaffinity purification of human erythrocyte prolidase. Clin Chim Acta 176:143–149PubMedGoogle Scholar
  25. Flentke GR, Munoz E, Huber BT et al (1991) Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci U S A 88:1556–1559PubMedGoogle Scholar
  26. Forlino A, Lupi A, Vaghi P et al (2002) Mutation analysis of five new patients affected by prolidase deficiency: the lack of enzyme activity causes necrosis-like cell death in cultured fibroblasts. Hum Genet 111:314–322PubMedGoogle Scholar
  27. Fülöp V, Böcskei Z, Polgár L (1998) Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis. Cell 94:161–170PubMedGoogle Scholar
  28. Ghosh M, Grunden AM, Dunn DM et al (1998) Characterization of native and recombinant forms of an unusual cobalt-dependent proline dipeptidase (prolidase) from the hyperthermophilic archaeon Pyrococcus furiosus. J Bacteriol 180:4781–4789PubMedGoogle Scholar
  29. Giustizieri ML, Albanesi C, Scarponi C et al (2002) Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am J Pathol 161:1409–1418PubMedGoogle Scholar
  30. Graham SC, Lilley PE, Lee M et al (2006) Kinetic and crystallographic analysis of mutant Escherichia coli aminopeptidase P: insights into substrate recognition and the mechanism of catalysis. Biochemistry 45:964–975PubMedGoogle Scholar
  31. Hechtman P (2001) Prolidase deficiency. In: Scriver CR, Beaudet AL, Sly D, Valle W (eds) The metabolic and molecular basis of inherited disease. McGraw Hill, New YorkGoogle Scholar
  32. Hechtman P, Richter A, Corman N et al (1988) In situ activation of human erythrocyte prolidase: potential for enzyme replacement therapy in prolidase deficiency. Pediatr Res 24:709–712PubMedGoogle Scholar
  33. Hedeager-Sørensen S, Kenny AJ (1985) Proteins of the kidney microvillar membrane. Purification and properties of carboxypeptidase P from pig kidneys. Biochem J 229:251–257PubMedGoogle Scholar
  34. Hershkovitz T, Hassoun G, Indelman M et al (2006) A homozygous missense mutation in PEPD encoding peptidase D causes prolidase deficiency associated with hyper-IgE syndrome. Clin Exp Dermatol 31:435–440PubMedGoogle Scholar
  35. House C, Baldwin GS, Kemp BE (1984) Synthetic peptide substrates for the membrane tyrosine protein kinase stimulated by epidermal growth factor. Eur J Biochem 140:363–367PubMedGoogle Scholar
  36. Hui KS, Lajtha A (1980) Activation and inhibition of cerebral prolidase. J Neurochem 35:489–494PubMedGoogle Scholar
  37. Hvizdos KM, Markham A (1999) Orlistat: a review of its use in the management of obesity. Drugs 58:743–760PubMedGoogle Scholar
  38. Jemec GB, Moe AT (1996) Topical treatment of skin ulcers in prolidase deficiency. Pediatr Dermatol 13:58–60PubMedGoogle Scholar
  39. Kikuchi S, Tanoue A, Endo F et al (2000) A novel nonsense mutation of the PEPD gene in a Japanese patient with prolidase deficiency. J Hum Genet 45:102–104PubMedGoogle Scholar
  40. Koshland DE (1993) Molecule of the year. Science 262:1953PubMedGoogle Scholar
  41. Kurien BT, Patel NC, Porter AC et al (2006) Prolidase deficiency and the biochemical assays used in its diagnosis. Anal Biochem 349:165–175PubMedGoogle Scholar
  42. Laitinen O (1975) Clinical applications of urinary hydroxyproline determination. Acta Med Scand Suppl 577:1–57PubMedGoogle Scholar
  43. Lapiere CM, Nusgens B (1969) Torpid skin wounds and collagen metabolism disorder. Arch Belg Dermatol Syphiligr 25:353–356PubMedGoogle Scholar
  44. Ledoux P, Scriver C, Hechtman P (1994) Four novel PEPD alleles causing prolidase deficiency. Am J Hum Genet 54:1014–1021PubMedGoogle Scholar
  45. Ledoux P, Scriver CR, Hechtman P (1996) Expression and molecular analysis of mutations in prolidase deficiency. Am J Hum Genet 59:1035–1039PubMedGoogle Scholar
  46. Liu G, Nakayama K, Sagara Y et al (2005) Characterization of prolidase activity in erythrocytes from a patient with prolidase deficiency: comparison with prolidase I and II purified from normal human erythrocytes. Clin Biochem 38:625–631PubMedGoogle Scholar
  47. Lowther WT, Matthews BW (2002) Metalloaminopeptidases: common functional themes in disparate structural surroundings. Chem Rev 102:4581–4608PubMedGoogle Scholar
  48. Lupi A, Casado B, Soli M et al (2002) Therapeutic apheresis exchange in two patients with prolidase deficiency. Br J Dermatol 147:1237–1240PubMedGoogle Scholar
  49. Lupi A, De Riso A, Della Torre S et al (2004) Characterization of a new PEPD allele causing prolidase deficiency in two unrelated patients: natural-occurrent mutations as a tool to investigate structure-function relationship. J Hum Genet 49:500–506PubMedGoogle Scholar
  50. Lupi A, Della Torre S, Campari E et al (2006a) Human recombinant prolidase from eukaryotic and prokaryotic sources. Expression, purification, characterization and long-term stability studies. FEBS J 273:5466–5478PubMedGoogle Scholar
  51. Lupi A, Rossi A, Campari E et al (2006b) Molecular characterization of six prolidase deficiency patients: identification of the first PEPD small duplication and of a mutation generating symptomatic and asymptomatic outcome within the same family. J Med Genet 43:e58PubMedGoogle Scholar
  52. Maes M, Lambeir A, Gilany K et al (2005) Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase (QPP)/dipeptidyl peptidase 7 (DPP7). Biochem J 386:315–324PubMedGoogle Scholar
  53. Maes M, Martinet W, Schrijvers D et al (2006) Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol 72:70–79PubMedGoogle Scholar
  54. Maes M, Scharpé S, De Meester I (2007) Dipeptidyl peptidase II (DPPII), a review. Clin Chim Acta 380:31–49PubMedGoogle Scholar
  55. Maher MJ, Ghosh M, Grunden AM et al (2004) Structure of the prolidase from Pyrococcus furiosus. Biochemistry 43:2771–2783PubMedGoogle Scholar
  56. Marcinkiewicz J, Chain BM (1993) Differential regulation of cytokine production by nitric oxide. Immunology 80:146–150PubMedGoogle Scholar
  57. Marcinkiewicz J (1997) Regulation of cytokine production by eicosanoids and nitric oxide. Arch Immunol Ther Exp 45:163–167Google Scholar
  58. Marcinkiewicz J, Grabowska A, Chain BM (1996) Is there a role for nitric oxide in regulation of T cell secretion of IL-2? J Immunol 156:4617–4621PubMedGoogle Scholar
  59. Marguet D, Baggio L, Kobayashi T et al (2000) Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 97:6874–6879PubMedGoogle Scholar
  60. Matsushima M, Takahashi T, Ichinose M et al (1991) Structural and immunological evidence for the identity of prolyl aminopeptidase with leucyl aminopeptidase. Biochem Biophys Res Commun 178:1459–1464PubMedGoogle Scholar
  61. McDonald JK, Ohkubo I (2004) Dipeptidyl-peptidase II. In: Barrett AJ RN, Woessner JF (eds) Handbook of proteolytic enzymes. Elsevier, LondonGoogle Scholar
  62. Mittal S, Song X, Vig BS et al (2007a) Proline prodrug of melphalan targeted to prolidase, a prodrug activating enzyme overexpressed in melanoma. Pharm Res 24:1290–1298PubMedGoogle Scholar
  63. Mittal S, Song X, Vig BS et al (2005) Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs. Mol Pharm 2:37–46PubMedGoogle Scholar
  64. Mittal S, Tsume Y, Landowski CP et al (2007b) Proline prodrug of melphalan, prophalan-L, demonstrates high therapeutic index in a murine melanoma model. Eur J Pharm Biopharm 67:752–758PubMedGoogle Scholar
  65. Miwa M, Ura M, Nishida M et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281PubMedGoogle Scholar
  66. Monafo V, Marseglia GL, Maghnie M et al (2000) Transient beneficial effect of GH replacement therapy and topical GH application on skin ulcers in a boy with prolidase deficiency. Pediatr Dermatol 17:227–230PubMedGoogle Scholar
  67. Morel et al (2007) Abstract presented at the 43rd annual symposium SSIEM, Hamburg, 4–7 September 2007Google Scholar
  68. Myara I, Cosson C, Moatti N et al (1994) Human kidney prolidase-purification, preincubation properties and immunological reactivity. Int J Biochem 26:207–214PubMedGoogle Scholar
  69. Nakayama K, Awata S, Zhang J et al (2003) Characteristics of prolidase from the erythrocytes of normal humans and patients with prolidase deficiency and their mother. Clin Chem Lab Med 41:1323–1328PubMedGoogle Scholar
  70. Ogata A, Tanaka S, Tomoda T et al (1981) Autosomal recessive prolidase deficiency. Three patients with recalcitrant ulcers. Arch Dermatol 117:689–697PubMedGoogle Scholar
  71. Olsen C, Wagtmann N (2002) Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene 299:185–193PubMedGoogle Scholar
  72. Oono T, Yasutomi H, Ohhashi T et al (1990) Characterization of fibroblast-derived prolidase. The presence of two forms of prolidase. J Dermatol Sci 1:319–323PubMedGoogle Scholar
  73. Perugini P, Hassan K, Genta I et al (2005) Intracellular delivery of liposome-encapsulated prolidase in cultured fibroblasts from prolidase-deficient patients. J Control Release 102:181–190PubMedGoogle Scholar
  74. Priestman DA, Butterworth J (1984) Prolidase deficiency: characteristics of human skin fibroblast prolidase using colorimetric and fluorimetric assays. J.Clin Chim Acta 142:263–271Google Scholar
  75. Richter AM, Lancaster GL, Choy FY et al (1989) Purification and characterization of activated human erythrocyte prolidase. Biochem Cell Biol 67:34–41PubMedCrossRefGoogle Scholar
  76. Roderick SL, Matthews BW (1993) Structure of the cobalt-dependent methionine aminopeptidase from Escherichia coli: a new type of proteolytic enzyme. Biochemistry 32:3907–3912PubMedGoogle Scholar
  77. Royce PM, Steinmann B (2002) Prolidase deficiency. In: Royce PM, Steinmann B (eds) Connective tissue and its heritable disorders. Wiley-Liss, New YorkGoogle Scholar
  78. Rundhaug JE (2005) Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9:267–285PubMedGoogle Scholar
  79. Schäffer MR, Efron PA, Thornton FJ et al (1997) Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 158:2375–2381PubMedGoogle Scholar
  80. Schweichel JU, Merker HJ (1973) The morphology of various types of cell death in prenatal tissues. Teratology 7:253–266Google Scholar
  81. Sheffield LJ, Schlesinger P, Faull K et al (1977) Iminopeptiduria, skin ulcerations, and edema in a boy with prolidase deficiency. J Pediatr 91:578–583PubMedGoogle Scholar
  82. Shrinath M, Walter JH, Haeney M et al (1997) Prolidase deficiency and systemic lupus erythematosus. Arch Dis Child 76:441–444PubMedCrossRefGoogle Scholar
  83. Sjostrom H, Noren O (1974) Structural properties of pig intestinal proline dipeptidase. Biochim Biophys Acta 359:177–185PubMedGoogle Scholar
  84. Songyang Z, Lu KP, Kwon YT et al (1996) A structural basis for substrate specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol 16:6486–6493PubMedGoogle Scholar
  85. Surazynski A, Donald SP, Cooper SK et al (2008) Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer 122:1435–1440PubMedGoogle Scholar
  86. Surazynski A, Liu Y, Miltyk W et al (2005) Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. J Cell Biochem 96:1086–1094PubMedGoogle Scholar
  87. Surazynski A, Palka J, Wolczynski S (2001) Phosphorylation of prolidase increases the enzyme activity. Mol Cell Biochem 220:95–101PubMedGoogle Scholar
  88. Tan F, Morris PW, Skidgel RA et al (1993) Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families. J Biol Chem 268:16631–16638PubMedGoogle Scholar
  89. Tanoue A, Endo F, Akaboshi I et al (1991) Molecular defect in siblings with prolidase deficiency and absence or presence of clinical symptoms. A 0.8-kb deletion with breakpoints at the short, direct repeat in the PEPD gene and synthesis of abnormal messenger RNA and inactive polypeptide. J Clin Invest 87:1171–1176PubMedGoogle Scholar
  90. Tanoue A, Endo F, Kitano A et al (1990a) A single nucleotide change in the prolidase gene in fibroblasts from two patients with polypeptide positive prolidase deficiency. Expression of the mutant enzyme in NIH 3T3 cells. J Clin Invest 86:351–355PubMedGoogle Scholar
  91. Tanoue A, Endo F, Matsuda I (1990b) Structural organization of the gene for human prolidase (peptidase D) and demonstration of a partial gene deletion in a patient with prolidase deficiency. J Biol Chem 265:11306–11311PubMedGoogle Scholar
  92. Vanhoof G, Goossens F, De Meester I et al (1995) Proline motifs in peptides and their biological processing. FASEB J:736–744Google Scholar
  93. Venturini M (2002) Rational development of capecitabine. Eur J Cancer 38(Suppl 2):3–9PubMedGoogle Scholar
  94. Viglio S, Annovazzi L, Conti B et al (2006) The role of emerging techniques in the investigation of prolidase deficiency: from diagnosis to the development of a possible therapeutical approach. J Chromatogr B Analyt Technol Biomed Life Sci 832:1–8PubMedGoogle Scholar
  95. Wang H, Kurien BT, Lundgren D et al (2006a) A nonsense mutation of PEPD in four Amish children with prolidase deficiency. Am J Med Genet A 140:580–585PubMedGoogle Scholar
  96. Wang SH, Zhi QW, Sun MJ (2005) Purification and characterization of recombinant human liver prolidase expressed in Saccharomyces cerevisiae. Arch Toxicol 79:253–259PubMedGoogle Scholar
  97. Wang SH, Zhi QW, Sun MJ (2006b) Dual activities of human prolidase. Toxicol In Vitro 20:71–77PubMedGoogle Scholar
  98. Wilce MC, Bond CS, Dixon NE et al (1998) Structure and mechanism of a proline-specific aminopeptidase from Escherichia coli. Proc Natl Acad Sci U S A 95:3472–3477PubMedGoogle Scholar
  99. Willingham K, Maher MJ, Grunden AM et al (2001) Crystallization and characterization of the prolidase from Pyrococcus furiosus. Acta Crystallogr D Biol Crystallogr 57:428–430PubMedGoogle Scholar
  100. Yaffe MB, Smerdon SJ (2004) The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. Annu Rev Biophys Biomol Struct 33:225–244PubMedGoogle Scholar
  101. Yaron A, Naider F (1993) Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 28:31–81PubMedGoogle Scholar
  102. Yasuda K, Ogata K, Kariya K et al (1999) Corticosteroid treatment of prolidase deficiency skin lesions by inhibiting iminodipeptide-primed neutrophil superoxide generation. Br J Dermatol 141:846–851PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • A. Lupi
    • 1
  • R. Tenni
    • 1
  • A. Rossi
    • 1
  • G. Cetta
    • 1
  • A. Forlino
    • 1
    Email author
  1. 1.Department of Biochemistry, Section of Medicine and PharmacyUniversity of PaviaPaviaItaly

Personalised recommendations